AG
AKBA icon

Advisor Group’s Akebia Therapeutics AKBA Stock Holding History

Advisor Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$72K Buy
11,139
+3,813
+52% +$18.1K ﹤0.01% 3168
2019
Q3 		$29K Sell
7,326
-74
-1% -$317 ﹤0.01% 3732
2019
Q2 		$36K Hold
7,400
– – ﹤0.01% 3574
2019
Q1 		$61K Sell
7,400
-2,519
-25% -$17.3K ﹤0.01% 3242
2018
Q4 		$54K Buy
9,919
+9,619
+3,206% +$75.3K ﹤0.01% 3121
2018
Q3 		$3K Sell
300
-357
-54% -$3.19K ﹤0.01% 4722
2018
Q2 		$7K Sell
657
-8
-1% -$80 ﹤0.01% 4226
2018
Q1 		$6K Sell
665
-1
-0.2% -$14 ﹤0.01% 4312
2017
Q4 		$10K Hold
666
– – ﹤0.01% 4067
2017
Q3 		$13K Buy
666
+133
+25% +$2.04K ﹤0.01% 3806
2017
Q2 		$7K Buy
533
+262
+97% +$3.32K ﹤0.01% 4075
2017
Q1 		$2K Sell
271
-16
-6% -$156 ﹤0.01% 4359
2016
Q4 		$3K Hold
287
– – ﹤0.01% 4094
2016
Q3 		$2K Buy
287
+97
+51% +$825 ﹤0.01% 4136
2016
Q2 		$1K Buy
+190
New +$1.66K ﹤0.01% 4196

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisor Group's AKBA Position: Q4 2019 in Review

Advisor Group increased its Akebia Therapeutics (AKBA) stake by 52% in Q4 2019, buying an estimated $18.1K and bringing the position to 11,139 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #3168.

Advisor Group first reported a position in AKBA in Q2 2016 and has held it in 15 quarters since. 153 funds tracked by Wall St. Rank hold AKBA as of Q4 2019.

  • Advisor Group held 11,139 shares of Akebia Therapeutics worth $72K as of Q4 2019.
  • Advisor Group bought 3,813 Akebia Therapeutics shares in Q4 2019, an estimated $18.1K.
  • Akebia Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3168 holding.
  • Advisor Group first reported a position in Akebia Therapeutics in Q2 2016 and has held it in 15 quarters since.
  • 153 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.